AstraZeneca (AZN) Gets a Buy from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on AstraZeneca, with a price target of £160.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Vosser is a 2-star analyst with an average return of 0.5% and a 45.23% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Sanofi.
In addition to J.P. Morgan, AstraZeneca also received a Buy from Barclays’s James Gordon CFA in a report issued today. However, yesterday, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca announces results of 3 trials of efzimfotase alfa
- Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
- AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy
- AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Guggenheim
- AstraZeneca’s OPTIMISE-CKD Update: What Dapagliflozin Real‑World Data Could Mean for AZN Investors
